VIATRIS INC. Increase (Decrease) in Inventories
VIATRIS INC. (VTRS) reported Increase (Decrease) in Inventories of $222.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInventories · last filed 2026-08-06
- VIATRIS INC. increase (decrease) in inventories for the quarter ending 2026-06-30 was $99.50M, a 155.13% increase year-over-year.
- VIATRIS INC. increase (decrease) in inventories for the quarter ending 2026-03-31 was $123.00M, a 36.50% decline year-over-year.
- VIATRIS INC. increase (decrease) in inventories for the quarter ending 2025-12-31 was -$15.80M, a 144.38% decline year-over-year.
- VIATRIS INC. increase (decrease) in inventories for the quarter ending 2025-09-30 was -$110.50M, a 185.66% decline year-over-year.
- VIATRIS INC. increase (decrease) in inventories for fiscal 2025 was $106.40M, a 85.29% decline from fiscal 2024.
- VIATRIS INC. increase (decrease) in inventories for fiscal 2024 was $723.40M, a 17.95% increase from fiscal 2023.
- VIATRIS INC. increase (decrease) in inventories for fiscal 2023 was $613.30M, a 136.34% increase from fiscal 2022.
- VIATRIS INC. increase (decrease) in inventories for fiscal 2022 was $259.50M, a 39.31% decline from fiscal 2021.
| Period end | Increase (Decrease) in Inventories 3 month | Increase (Decrease) in Inventories 6 month | Increase (Decrease) in Inventories 9 month | Increase (Decrease) in Inventories 12 month |
|---|---|---|---|---|
| 2026-06-30 | $99.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $222.50M 10-Q · filed 2026-08-06 | $206.70M derived: sum of 3 quarters · filed 2026-08-06 | $96.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $123.00M 10-Q · filed 2026-05-07 | $107.20M derived: sum of 2 quarters · filed 2026-05-07 | -$3.30M derived: sum of 3 quarters · filed 2026-05-07 | $35.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$15.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$126.30M derived: sum of 2 quarters · filed 2026-02-26 | -$87.30M derived: sum of 3 quarters · filed 2026-08-06 | $106.40M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$110.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$71.50M derived: sum of 2 quarters · filed 2026-08-06 | $122.20M 10-Q · filed 2025-11-06 | $157.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $39.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $232.70M 10-Q · filed 2026-08-06 | $268.30M derived: sum of 3 quarters · filed 2026-08-06 | $397.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $193.70M 10-Q · filed 2026-05-07 | $229.30M derived: sum of 2 quarters · filed 2026-05-07 | $358.30M derived: sum of 3 quarters · filed 2026-05-07 | $546.70M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $35.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $164.60M derived: sum of 2 quarters · filed 2026-02-26 | $353.00M derived: sum of 3 quarters · filed 2026-02-26 | $723.40M 10-K · filed 2026-02-26 |
| 2024-09-30 | $129.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $317.40M derived: sum of 2 quarters · filed 2025-11-06 | $687.80M 10-Q · filed 2025-11-06 | $815.40M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $188.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $558.80M 10-Q · filed 2025-08-07 | $686.40M derived: sum of 3 quarters · filed 2026-02-26 | $905.60M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $370.40M 10-Q · filed 2025-05-08 | $498.00M derived: sum of 2 quarters · filed 2026-02-26 | $717.20M derived: sum of 3 quarters · filed 2026-02-26 | $832.60M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $127.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $346.80M derived: sum of 2 quarters · filed 2026-02-26 | $462.20M derived: sum of 3 quarters · filed 2026-02-26 | $613.30M 10-K · filed 2026-02-26 |
| 2023-09-30 | $219.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $334.60M derived: sum of 2 quarters · filed 2024-11-07 | $485.70M 10-Q · filed 2024-11-07 | $305.60M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $115.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $266.50M 10-Q · filed 2024-08-08 | $86.40M derived: sum of 3 quarters · filed 2025-02-27 | $255.90M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $151.10M 10-Q · filed 2024-05-09 | -$29.00M derived: sum of 2 quarters · filed 2025-02-27 | $140.50M derived: sum of 3 quarters · filed 2025-02-27 | $341.50M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$180.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$10.60M derived: sum of 2 quarters · filed 2025-02-27 | $190.40M derived: sum of 3 quarters · filed 2025-02-27 | $259.50M 10-K · filed 2025-02-27 |
| 2022-09-30 | $169.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $370.50M derived: sum of 2 quarters · filed 2023-11-08 | $439.60M 10-Q · filed 2023-11-08 | $516.10M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $201.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $270.10M 10-Q · filed 2023-08-07 | $346.60M derived: sum of 3 quarters · filed 2024-02-28 | $356.70M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $69.10M 10-Q · filed 2023-05-08 | $145.60M derived: sum of 2 quarters · filed 2024-02-28 | $155.70M derived: sum of 3 quarters · filed 2024-02-28 | $293.30M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $76.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $86.60M derived: sum of 2 quarters · filed 2024-02-28 | $224.20M derived: sum of 3 quarters · filed 2024-02-28 | $427.60M 10-K · filed 2024-02-28 |
| 2021-09-30 | $10.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $147.70M derived: sum of 2 quarters · filed 2022-11-07 | $351.10M 10-Q · filed 2022-11-07 | $560.60M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $137.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $341.00M 10-Q · filed 2022-08-08 | $550.50M derived: sum of 3 quarters · filed 2023-02-27 | $807.10M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $203.40M 10-Q · filed 2022-05-09 | $412.90M derived: sum of 2 quarters · filed 2023-02-27 | $669.50M derived: sum of 3 quarters · filed 2023-02-27 | $813.50M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $209.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $466.10M derived: sum of 2 quarters · filed 2023-02-27 | $610.10M derived: sum of 3 quarters · filed 2023-02-27 | $741.90M 10-K · filed 2023-02-27 |
| 2020-09-30 | $256.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $400.60M derived: sum of 2 quarters · filed 2021-11-08 | $532.40M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $144.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $275.80M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $131.80M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $512.90M 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $547.60M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |